BiomX Ltd. (previously named MBcure), a Ness Ziona, Israel-based microbiome therapeutics company, raised $24m in a Series A financing.
The round was led by OrbiMed, Johnson & Johnson Innovation – JJDC, Inc. and Takeda Ventures, Inc. with participation from Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors.
The company intends to use the funds to advance its novel therapeutic pipeline towards clinical stages and to continue enhancing its proprietary microbiome modulation platform technologies.
Founded in the FutuRx Ltd. incubator, with the support of the Israel Innovation Authority, and led by Jonathan Solomon, CEO, BiomX focuses on developing novel therapeutics to alleviate human diseases stemming from dysbiosis of the microbiome. The company offers a solution from target discovery to development of therapeutic compounds, with capabilities to precisely modulate the microbiome and restore microbial balance through adding or eradicating bacteria with both native and synthetically altered phages (viruses that attack bacteria).
Its therapeutic pipeline consists of products for the treatment of acne, Inflammatory Bowel Disease (IBD), cancer, and therapeutics that modulate the microbiome for improved performance of immuno-oncology drugs.
BiomX’s microbiome modulation technologies are based on the science and research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.